Home
/
Pacira BioSciences, Inc.
/
Financials
/
Quarterly
Pacira BioSciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Pacira BioSciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2019
Sep 30, 2019
$104.69M
Nov 8, 2019
Q2
2019
Jun 30, 2019
$102.60M
Aug 8, 2019
Q1
2019
Mar 31, 2019
$91.31M
May 2, 2019
Q3
2019
Sep 30, 2018
$83.45M
Nov 8, 2019
Q2
2019
Jun 30, 2018
$84.11M
Aug 8, 2019
Q1
2019
Mar 31, 2018
$74.61M
May 2, 2019
Q3
2018
Sep 30, 2017
$67.34M
Nov 1, 2018
Q2
2018
Jun 30, 2017
$70.93M
Aug 2, 2018
Q1
2018
Mar 31, 2017
$69.28M
May 3, 2018
Q3
2017
Sep 30, 2016
$68.36M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$69.64M
Aug 2, 2017
Q1
2017
Mar 31, 2016
$65.47M
May 4, 2017
Q3
2016
Sep 30, 2015
$62.21M
Nov 2, 2016
Q2
2016
Jun 30, 2015
$59.15M
Aug 4, 2016
Q1
2016
Mar 31, 2015
$58.32M
May 2, 2016
Q3
2015
Sep 30, 2014
$52.05M
Oct 27, 2015
Q2
2015
Jun 30, 2014
$47.17M
Jul 30, 2015
Q1
2015
Mar 31, 2014
$36.66M
Apr 30, 2015
Q3
2014
Sep 30, 2013
$23.26M
Oct 30, 2014
Q2
2014
Jun 30, 2013
$17.14M
Jul 31, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$179.52M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$181.10M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$168.92M
May 8, 2025
Q3
2025
Sep 30, 2024
$168.57M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$178.02M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$167.12M
May 8, 2025
Q3
2024
Sep 30, 2023
$163.93M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$169.47M
Jul 30, 2024
Q1
2024
Mar 31, 2023
$160.34M
May 7, 2024
Q3
2023
Sep 30, 2022
$167.47M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$169.41M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$157.99M
May 3, 2023
Q3
2022
Sep 30, 2021
$127.72M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$135.59M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$119.03M
May 4, 2022
Q3
2021
Sep 30, 2020
$117.48M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$75.51M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$105.68M
May 4, 2021
Q3
2020
Sep 30, 2019
$104.35M
Oct 30, 2020
Q2
2020
Jun 30, 2019
$101.82M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.43M
Nov 6, 2025
Q2
2025
Jun 30, 2025
($4.85M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
$4.81M
May 8, 2025
Q3
2025
Sep 30, 2024
($143.47M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$18.89M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$8.98M
May 8, 2025
Q3
2024
Sep 30, 2023
$10.86M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$25.76M
Jul 30, 2024
Q1
2024
Mar 31, 2023
($19.54M)
May 7, 2024
Q3
2023
Sep 30, 2022
($693.0K)
Nov 2, 2023
Q2
2023
Jun 30, 2022
$19.88M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$6.83M
May 3, 2023
Q3
2022
Sep 30, 2021
$17.66M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$19.08M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$10.37M
May 4, 2022
Q3
2021
Sep 30, 2020
$130.12M
Nov 3, 2021
Q2
2021
Jun 30, 2020
($7.27M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
$8.16M
May 4, 2021
Q3
2020
Sep 30, 2019
($6.09M)
Oct 30, 2020
Q2
2020
Jun 30, 2019
$2.73M
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$6.36M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$8.50M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$1.99M
May 8, 2025
Q3
2025
Sep 30, 2024
($139.53M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$28.24M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$13.21M
May 8, 2025
Q3
2024
Sep 30, 2023
$17.72M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$39.88M
Jul 30, 2024
Q1
2024
Mar 31, 2023
($3.09M)
May 7, 2024
Q3
2023
Sep 30, 2022
$21.29M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$31.24M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$17.39M
May 3, 2023
Q3
2022
Sep 30, 2021
$31.43M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$34.84M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$19.44M
May 4, 2022
Q3
2021
Sep 30, 2020
$17.62M
Nov 3, 2021
Q2
2021
Jun 30, 2020
($7.15M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
$17.09M
May 4, 2021
Q3
2020
Sep 30, 2019
$2.41M
Oct 30, 2020
Q2
2020
Jun 30, 2019
$5.28M
Aug 6, 2020